[1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
AssigneeJanssen Pharmaceutica NV
InventorsPetrus Jacobus Johannes Antonius Buijnsters, Henricus Jacobus Maria Gijsen, Wilhelmus Helena Ignatius Maria Drinkenburg, Abdallah Ahnaou
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivative as inhibitor of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compound, to processes for preparing such compound and compositions, and to the use of such compound and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
Claims11
A compound having the formula (1)
- or a pharmaceutically acceptable salt or a solvate thereof.
A method of treatment comprising administering to a patient in need of treatment for a central nervous system disorder selected from the group of Alzheimer's disease;
- stroke;
- a learning disorder;
- a disorder or condition comprising as a symptom a deficiency in attention and/or cognition;
- mild cognitive impairment;
- age-related cognitive impairment;
- cognitive impairment related to perception, concentration, learning or memory;
- and memory disorders, a therapeutically effective amount of a compound having the formula (1)
- or a pharmaceutically acceptable salt or a solvate thereof.
Dependencies are inferred from the claim text.